A novel, rapid method to detect infectious HIV-1 from plasma of persons infected with HIV-1

Journal of Virological Methods

Volumn 165, Issue 1, 2010, Pages 90-96

  Cornall, Alyssa ^a,b   Sharma, Laveena ^a,b   Solomon, Ajantha ^a,b   Gorry, Paul R ^b,c,d   Crowe, Suzanne M ^a,b,c   Cameron, Paul U ^a,b   Lewin, Sharon R ^a,b,c  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BURNET INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Co receptor; HIV 1; Plasma

Indexed keywords

ACID CITRATE DEXTROSE; EDETIC ACID; HEPARIN; VIRUS RNA;

ARTICLE; BLOOD CLOTTING; BLOOD CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS LOAD;

ANTICOAGULANTS; CELL LINE; HEPARIN; HIV INFECTIONS; HIV-1; HUMANS; PLASMA; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; REPLICATION COMPETENT VIRUSES;

EID: 77649341752     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.01.010     Document Type: Article

References (42)

1. Abraha A., Troyer R., Quinones-Mateu M., and Arts E. Methods to determine HIV-1 ex-vivo fitness. Methods in Molecular Biology 304 (2005) 355-368
2. Ali A., and Yang O. A novel small reporter gene and HIV-1 fitness assay. Journal of Virological Methods 133 (2006) 41-47
3. Andreoni M., Sarmati L., Parisi S.G., Ercoli L., and Rocchi G. Efficient and reproducible new semimicromethod for the detection and titration of HIV in human plasma. Journal of Medical Virology 38 (1992) 207-213
4. Baba M., Pauwels R., Balzarini J., Arnout J., Desmyter J., and Clercq E.D. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proceedings of the National Academy of Sciences of the United States of America 85 (1988) 6132-6136
5. Bridger G., Skerlj R., Thornton D., Padmanabhan S., Martellucci S., Henson G., Abrams M., Yamamoto N., De Vreese K., Pauwels R., and De Clercq E. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. Journal of Medicinal Chemistry 38 (1995) 366-378
6. Bruce S. The effect of calcium on fibrinolysis in vitro. Journal of Clinical Pathology 17 (1964) 282-286
7. Cilliers T., Nhlapo J., Coetzer M., Orlovic D., Ketas T., Olson W.C., Moore J.P., Trkola A., and Morris L. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. Journal of Virology 77 (2003) 4449-4456
8. Connor R.I., and Ho D.D. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. Journal of Virology 68 (1994) 4400-4408
9. Coombs R.W., Collier A.C., Allain J.-P., Nikora B., Leuther M., Gjerset G.F., and Corey L. Plasma viremia in human immunodeficiency virus infection. The New England Journal of Medicine 321 (1989) 1626-1631
10. Coombs R.W., Henrard D.R., Mehaffy W.F., Gibson J., Eggert E., Quinn T.C., and Phillips J. Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction. Journal of Clinical Microbiology 31 (1993) 1980-1986
11. Croteau G., Doyon L., Thibeault D., McKercher G., Pilote L., and Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. Journal of Virology 71 (1997) 1089-1096
12. De Clercq E., Yamamoto N., Pauwels R., Balzarini J., Witvrouw M., De Vreese K., Debyser Z., Rosenwirth B., Peichl P., Datema R., Thornton D., Skerlj R., Gaul F., Padmanabhan S., Bridger G., Henson G., and Abrams M. Highly potent and selective inhibition of human. Immunodeficiency virus by the bicyclam derivative JM3100. Antimicrobial Agents and Chemotherapy 38 (1994) 668-674
13. DHHS Panel on Antiretroviral guidelines for adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents (2008), Department of health and human Services pp. 1-139
14. Gorry P.R., Bristol G., Zack J.A., Ritola K., Swanstrom R., Birch C.J., Bell J.E., Bannert N., Crawford K., Wang H., Schols D., Clercq E.D., Kunstman K., Wolinsky S.M., and Gabuzda D. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. Journal of Virology 75 (2001) 10073-10089
15. Hardy J.J., Carrell N.A., and McDonagh J. Calcium ion functions in fibrinogen conversion to fibrin. Annals of the New York Academy of Sciences 408 (1983) 279-287
16. Harrigan P., Bloor S., and Larder B.A. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. Journal of Virology 72 (1998) 3773-3778
17. Harrop H.A., and Rider C.C. Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4. Glycobiology 8 (1998) 131-137
18. Hartung S., Boller K., Cichutek K., Norley S.G., and Kurth R. Quantitation of a lentivirus in its natural host: simian immunodeficiency virus in African green monkeys. Journal of Virology 66 (1992) 2143-2149
19. Hendrix C., Flexner C., MacFarland R., Giandomenico C., Fuchs E., Redpath E., Bridger G., and Henson G. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrobial Agents and Chemotherapy 44 (2000) 1667-1673
20. Hertogs K., Thune M.-P.D.B., Miller V., Ivens T., Schel P., Cauwenberge A.V., Eynde C.V.D., Gerwen V.V., Azijn H., Houtte M.V., Peeters F., Staszewski S., Conant M., Bloor S., Kemp S., Larder B., and Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrobial Agents and Chemotherapy 42 (1998) 269-276
21. Ho D.D., Moudgil T., and Alam M. Quantitation of human immunodeficieny virus type 1 in the blood of infected persons. The New England Journal of Medicine 321 (1989) 1621-1625
22. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., and Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 (1995) 123-126
23. Lathey J.L., Fiscus S.A., Rasheed S., Kappes J.C., Griffith B.P., Elbeik T., Spector S.A., and Reichelderfer P.S. Optimization of quantitative culture assay for human immunodeficiency virus from plasma. Journal of Clinical Microbiology 32 (1994) 3064-3067
24. Lewis M., Balamurugan A., Ohno A., Kilpatrick S., Ng H., and Yang O. Functional adaptation of Nef to the immune milieu of HIV-1 infection in vivo. Journal of Immunology 180 (2008) 4075-4081
25. Lu J., Sista P., Giguel F., Greenberg M., and Kuritzkes D.R. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). Journal of Virology 78 (2004) 4628-4637
26. Lyttleton J.W. The antithrombin activity of heparin. The Biochemical Journal 58 (1954) 15-23
27. Malet I., Delelis O., Soulie C., Wirden M., Tchertanov L., Mottaz P., Peytavin G., Katlama C., Mouscadet J.F., Calvez V., and Marcelin A.G. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. The Journal of Antimicrobial Chemotherapy 63 (2009) 795-804
28. Mondor I., Ugolini S., and Sattentau Q.J. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. Journal of Virology 72 (1998) 3623-3634
29. Morner A., Bjorndal A., KewalRamani V., Littman D., Inoue R., Thorstensson R., Fenyo E., and Bjorling E. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. Journal of Virology 73 (1999) 2342-2349
30. Mosesson M.W., Siebenlist K.R., and Meh D.A. The structure and biological features of fibrinogen and fibrin. Annals of the New York Academy of Sciences 936 (2001) 11-30
31. Neumann T., Hagmann I., Lohrengel S., Heil M.L., Derdeyn C.A., Krausslich H.-G., and Dittmar M.T. T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. Virology 333 (2005) 251-262
32. Pan L.-Z., Werner A., and Levy J.A. Detection of plasma viremia in human immunodeficiency virus-infected individuals at all clinical stages. Journal of Clinical Microbiology 31 (1993) 283-288
33. Piatak Jr. M., Saag M.S., Yang L.C., Clark S.J., Kappes J.C., Luk K.-C., Hahn B.H., Shaw G.M., and Lifson J.D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR (polymerase chain reaction). Science 259 (1993) 1749-1754
34. Rizzardi G.P., Boer R.J.D., Hoover S., Tambussi G., Chapuis A., Halkic N., Bart P.-A., Miller V., Staszewski S., Notermans D.W., Perrin L., Fox C.H., Lange J.M.A., Lazzarin A., and Pantaleo G. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. Journal of Clinical Investigations 105 (2000) 777-782
35. Rusert P., Fischer M., Joos B., Leemann C., Kuster H., Flepp M., Bonhoeffer S., Gunthard H.F., and Trkola A. Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology 326 (2004) 113-129
36. Sanchez-Merino V., Nie S., and Luzuriaga K. HIV-1-specific CD8+ T cell responses and viral evolution in women and infants. The Journal of Immunology 175 (2005) 6976-6986
37. Vernazza P.L., Eron J.J., and Fiscus S.A. Loss of infectivity ex vivo in plasma of human immunodeficiency virus-infected patients correlates with a high CD4 cell count. Journal of Infectious Diseases 168 (1993) 1269-1272
38. Walker D.K., Abel S., Comby P., Muirhead G.J., Nedderman A.N.R., and Smith D.A. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metabolism and Disposition 33 (2005) 587-595
39. Weber J., Weberova J., Carobene M., Mirza M., Martinez-Picado J., Kazanjian P., and Quinones-Mateu M.E. Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. Journal of Virological Methods 136 (2006) 102-117
40. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H., Saag M.S., and Shaw G.M. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 (1995) 117-122
41. Whitcomb J.M., Huang W., Fransen S., Limoli K., Toma J., Wrin T., Chappey C., Kiss L.D.B., Paxinos E.E., and Petropoulos C.J. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrobial Agents and Chemotherapy 51 (2007) 566-575
42. Yamada O., Matsumoto T., Sasoaka R., and Kurimura T. Variations in growth capacity of HIV in peripheral blood mononuclear cell preparations from different individuals. AIDS 4 (1990) 35-40